The metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations.

IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM

Expert Review of Endocrinology & Metabolism Pub Date : 2022-11-01 DOI:10.1080/17446651.2022.2144829

Giovanni Corona, Giulia Rastrelli, Paolo Comeglio, Federica Guaraldi, Diego Mazzatenta, Alessandra Sforza, Linda Vignozzi, Mario Maggi

{"title":"The metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations.","authors":"Giovanni Corona, Giulia Rastrelli, Paolo Comeglio, Federica Guaraldi, Diego Mazzatenta, Alessandra Sforza, Linda Vignozzi, Mario Maggi","doi":"10.1080/17446651.2022.2144829","DOIUrl":null,"url":null,"abstract":"Introduction: Hyperprolactinemia has been proven to induce hypogonadism and metabolic derangements in both genders, while the consequences of prolactin (PRL) deficiency have been poorly investigated.Areas covered: To systematically review and analyze data from clinical studies focusing on the metabolic consequences of abnormally high prolactin levels (HPRL) and low prolactin levels (LPRL). In addition, data from preclinical studies about underlying pathophysiological mechanisms were summarized and discussed.Expert opinion: PRL contributes to providing the correct amount of energy to support the mother and the fetus/offspring during pregnancy and lactation, but it also has a homeostatic role. Pathological PRL elevation beyond these physiological conditions, but also its reduction, impairs metabolism and body composition in both genders, increasing the risk of diabetes and cardiovascular events. Hence, hypoprolactinemia should be avoided as much as possible during treatment with dopamine agonists for prolactinomas. Patients with hypoprolactinemia, because of endogenous or iatrogenic conditions, deserve, as those with hyperprolactinemia, careful metabolic assessment.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"17 6","pages":"533-545"},"PeriodicalIF":2.7000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17446651.2022.2144829","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 2

Abstract

Introduction: Hyperprolactinemia has been proven to induce hypogonadism and metabolic derangements in both genders, while the consequences of prolactin (PRL) deficiency have been poorly investigated.

Areas covered: To systematically review and analyze data from clinical studies focusing on the metabolic consequences of abnormally high prolactin levels (HPRL) and low prolactin levels (LPRL). In addition, data from preclinical studies about underlying pathophysiological mechanisms were summarized and discussed.

Expert opinion: PRL contributes to providing the correct amount of energy to support the mother and the fetus/offspring during pregnancy and lactation, but it also has a homeostatic role. Pathological PRL elevation beyond these physiological conditions, but also its reduction, impairs metabolism and body composition in both genders, increasing the risk of diabetes and cardiovascular events. Hence, hypoprolactinemia should be avoided as much as possible during treatment with dopamine agonists for prolactinomas. Patients with hypoprolactinemia, because of endogenous or iatrogenic conditions, deserve, as those with hyperprolactinemia, careful metabolic assessment.

查看原文本刊更多论文

催乳素的代谢作用:系统综述、荟萃分析和临床前考虑。

导论:高催乳素血症已被证明会导致两性性腺功能减退和代谢紊乱，而催乳素(PRL)缺乏的后果尚未得到充分研究。涵盖领域:系统回顾和分析临床研究数据，重点关注异常高催乳素水平(HPRL)和低催乳素水平(LPRL)的代谢后果。此外，总结和讨论了临床前研究中关于潜在病理生理机制的数据。专家意见:PRL有助于在怀孕和哺乳期间为母亲和胎儿/后代提供正确数量的能量，但它也有一个自我平衡的作用。病理性PRL升高超出这些生理条件，但其降低，损害代谢和身体成分的男女，增加患糖尿病和心血管事件的风险。因此，在使用多巴胺激动剂治疗催乳素瘤期间，应尽可能避免低催乳素血症。低催乳素血症患者，由于内源性或医源性疾病，应与高催乳素血症患者一样，仔细进行代谢评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Endocrinology & Metabolism ENDOCRINOLOGY & METABOLISM-

CiteScore

4.80

自引率

0.00%

发文量

期刊介绍： Implicated in a plethora of regulatory dysfunctions involving growth and development, metabolism, electrolyte balances and reproduction, endocrine disruption is one of the highest priority research topics in the world. As a result, we are now in a position to better detect, characterize and overcome the damage mediated by adverse interaction with the endocrine system. Expert Review of Endocrinology and Metabolism (ISSN 1744-6651), provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology.